Semaglutide vs Cagrilintide: Comparing Next-Gen Weight Loss Peptides

By NorthPeptide Research Team · April 7, 2026

Two Peptides, Two Pathways

The search for more effective metabolic interventions has produced two of the most discussed research peptides of the past decade — semaglutide and cagrilintide. Both target body weight regulation, but they do so through fundamentally different biological mechanisms. Semaglutide mimics an incretin hormone. Cagrilintide mimics a pancreatic hormone involved in post-meal satiety. Understanding these differences is essential for interpreting the clinical data and appreciating why researchers became interested in combining them.

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It entered clinical use for type 2 diabetes under the name Ozempic and for weight management under the name Wegovy. Its impact on clinical weight loss research has been difficult to overstate — the STEP trial program consistently demonstrated 15–17% reductions in body weight in non-diabetic adults, outcomes that reshaped how researchers and clinicians think about pharmacological approaches to obesity.

Cagrilintide is a long-acting amylin analog, also developed by Novo Nordisk. It targets an entirely separate receptor system — the amylin receptor complex — and signals through brain regions that are distinct from the GLP-1 pathway. In Phase 2 trials as a monotherapy, it produced meaningful weight reductions. But it was the Phase 3 combination trial data that drew the most attention from researchers.

Semaglutide: GLP-1 Receptor Agonism

Semaglutide is a 31-amino-acid analog of native human GLP-1(7-37) with three structural modifications that extend its half-life from approximately 2 minutes to approximately 7 days. A C18 fatty acid chain enables reversible albumin binding. An amino acid substitution at position 8 confers resistance to DPP-4 degradation. A substitution at position 34 directs the fatty acid to the correct attachment site. The result is a compound stable enough for once-weekly subcutaneous dosing.

GLP-1 receptors are expressed throughout the body, but for weight regulation the most relevant sites are in the hypothalamus — particularly the arcuate nucleus, which integrates hunger and satiety signals — and in the hindbrain nucleus tractus solitarius. GLP-1 receptor activation in these areas suppresses appetite, promotes satiety, and reduces food intake. GLP-1 receptors are also expressed in the stomach, where activation slows gastric emptying, prolonging the sensation of fullness after meals.

Secondary mechanisms include effects on dopamine reward pathways. GLP-1 receptors are expressed in the ventral tegmental area and nucleus accumbens. Research suggests that GLP-1 receptor activation in these areas reduces the hedonic drive to eat — the desire for food that is independent of caloric need — which may explain why semaglutide appears to reduce food cravings and not merely physical hunger.

The clinical evidence for semaglutide’s weight effects comes primarily from the STEP trial program:

• STEP 1 (n=1,961, non-diabetic adults with BMI ≥30): 2.4 mg/week semaglutide produced a mean weight reduction of 14.9% vs. 2.4% for placebo over 68 weeks. (Wilding et al., NEJM 2021)
• STEP 2 (n=1,210, type 2 diabetes): 2.4 mg/week produced a mean weight reduction of 9.6% vs. 3.4% for placebo over 68 weeks.
• STEP 5 (2-year extension): Weight reduction was sustained at approximately 15.2% at 104 weeks, demonstrating durable efficacy.
• SELECT (cardiovascular outcomes, n=17,604): Semaglutide reduced major adverse cardiovascular events (MACE) by 20% vs. placebo in adults with obesity and established cardiovascular disease, even without diabetes — the first obesity intervention to demonstrate this.

Cagrilintide: Amylin Receptor Agonism

Cagrilintide (NN9838 / AM833) is a synthetic analog of amylin, a 37-amino-acid pancreatic hormone co-secreted with insulin from beta cells in response to food intake. Native amylin has a circulating half-life of approximately 13 minutes and is prone to aggregation, limiting its therapeutic utility. Cagrilintide was engineered with a C18 fatty diacid conjugation for albumin binding (achieving a ~7-day half-life) and targeted amino acid substitutions that reduce aggregation tendency — the same properties that made earlier amylin analog pramlintide require three-times-daily injections.

Amylin receptors are heterodimers formed by the calcitonin receptor (CTR) in combination with one of three receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). These receptor complexes are highly expressed in the area postrema (AP) and nucleus tractus solitarius (NTS) in the brainstem — regions that integrate visceral satiety signals — and in the hypothalamic arcuate nucleus. This distribution overlaps partially with GLP-1 receptor expression but involves distinct neuronal populations and intracellular signaling cascades.

Amylin receptor activation produces satiety signaling through mechanisms that are different from those of GLP-1:

• Post-meal satiety signaling: Amylin is released in proportion to meal size. Its receptor activation in the AP/NTS signals meal completion and contributes to the cessation of eating. This is a distinct signal from the pre-meal and ongoing hunger suppression produced by GLP-1 agonists.
• Gastric emptying: Like GLP-1 agonists, amylin slows gastric emptying, contributing to post-meal fullness, though the magnitude and duration differ.
• Glucagon suppression: Amylin receptor activation suppresses post-meal glucagon secretion, complementing insulin’s effects on glucose disposal.
• Long-term energy balance: Chronic amylin receptor signaling in the hypothalamus has been associated with changes in body weight setpoint regulation in preclinical models, a mechanism that may explain the durability of weight effects.

Cagrilintide’s Phase 2 monotherapy data (32-week trial, n=706, four doses from 0.3 mg to 4.5 mg weekly) showed dose-dependent weight reductions of up to 10.8% from baseline at the highest dose — meaningful, but less than semaglutide as a monotherapy. (Enebo et al., Lancet 2021)

The REDEFINE Trials: CagriSema Combination Data

The most significant development in cagrilintide research has been its evaluation in combination with semaglutide as the fixed-ratio co-formulation CagriSema. The rationale for this combination is mechanistically compelling: GLP-1 receptor agonism and amylin receptor agonism signal through distinct receptor systems in partially overlapping but distinct brain regions, activating different intracellular pathways and producing complementary physiological effects. If the mechanisms are truly independent, combination therapy might be expected to produce additive or synergistic weight reduction.

The Phase 2 CagriSema data supported this hypothesis. A 32-week trial (n=92) comparing CagriSema (2.4 mg semaglutide + 2.4 mg cagrilintide) against semaglutide monotherapy (2.4 mg) and cagrilintide monotherapy (2.4 mg) found:

• CagriSema: Mean weight reduction of 17.1%
• Semaglutide alone: Mean weight reduction of 9.8%
• Cagrilintide alone: Mean weight reduction of 8.1%

The combination effect substantially exceeded the sum of the monotherapy effects — a finding consistent with genuine mechanistic synergy rather than simple addition. (Lau et al., Lancet 2023)

The REDEFINE 1 Phase 3 trial (n=3,400, adults with obesity without diabetes, 68 weeks) produced the headline results that placed CagriSema among the most potent metabolic research combinations studied to date. Preliminary results reported a mean weight reduction of approximately 22.7% — the highest efficacy observed in a Phase 3 weight management trial as of early 2026. Importantly, a substantial proportion of participants (approximately 40%) achieved weight reductions of 25% or more.

The REDEFINE 2 trial evaluated the combination in type 2 diabetes, where the effect on body weight was somewhat attenuated (as is typical of all GLP-1-class compounds in diabetic populations) but still substantial, with meaningful improvements in HbA1c.

Mechanism Comparison: What’s Different, What Overlaps

Side Effect Profiles

Both compounds share a broadly similar gastrointestinal side effect profile, which is expected given that both slow gastric motility. The most commonly reported adverse effects in clinical trials include:

• Nausea — the most frequent adverse event for both, particularly during dose escalation. Typically transient and resolving within weeks as the body adapts.
• Vomiting and diarrhea — reported in a minority of participants, generally mild to moderate severity.
• Constipation — more commonly associated with semaglutide due to its stronger gastric emptying delay.
• Injection site reactions — mild local reactions reported with both compounds.

In the CagriSema combination trials, the GI side effect rates were not dramatically higher than either monotherapy, which researchers interpreted as potentially reflecting the overlapping (rather than additive) nature of GI effects from the two compounds. This is mechanistically plausible: both compounds slow gastric emptying through partially shared downstream pathways, so the incremental GI burden of adding cagrilintide to semaglutide may be less than linear.

A key differentiation between the compounds’ side effect profiles concerns hypoglycemia risk. Semaglutide’s insulin secretory effect is glucose-dependent — it enhances insulin release only when blood glucose is elevated, substantially reducing hypoglycemia risk compared to older antidiabetic medications. Cagrilintide suppresses glucagon post-meal but does not directly stimulate insulin secretion. In the CagriSema diabetic trials, hypoglycemia rates were carefully monitored and remained within acceptable bounds with appropriate antidiabetic medication adjustment.

Research Outlook

As of 2026, the research landscape for these two compounds is moving in distinct directions. Semaglutide has completed its major Phase 3 programs and has extensive real-world data accumulating across millions of patients. Research attention has now shifted to longer-term cardiovascular outcomes (SELECT follow-up), potential applications in non-alcoholic steatohepatitis (NASH), Alzheimer’s disease risk modification, and addiction medicine.

Cagrilintide’s most important role in the near-term research literature is as a component of the CagriSema combination. The REDEFINE program is the critical Phase 3 dataset, and regulatory decisions about this combination will shape how amylin receptor agonism is understood in metabolic medicine. There is also ongoing mechanistic research into whether the combination’s synergy is driven primarily by complementary CNS pathways, complementary gastric effects, or both.

For researchers studying peptide mechanisms in metabolic regulation, the semaglutide-cagrilintide story is instructive: targeting two distinct but complementary receptor systems within the same physiological outcome (energy balance) appears to produce non-linear efficacy gains. This principle — mechanistic complementarity rather than pathway redundancy — is likely to guide peptide combination research in the coming decade.